ASCO 2020：11项中国研究崭露头角口头报告，17项Poster报告

曾受当今世界取而代之冠SARS影响，延后于5同年29日~6同年2日在芝加哥举行的宾夕法尼亚州诊疗总亦会（ASCO）高峰亦会今年将首次以线上形式承办，这是目前最大规模的线上盛宴。时至今日，大亦会的简短题目公布，合共103个sessions，中所国合共约11项研究课题崭露头角口头报告，17项崭露头角Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或卡马替尼加卡培他中洲可用HER2+前列腺癌乳腺白血病（PHOEBE）：一项III期随机试制。

大舞台：前列腺癌乳腺白血病

所写：中所国医学科学院疗养院徐兵河讲师、马飞讲师，上海交通大学附属疗养院胡夕春讲师等

简短号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可动手术三基本特征性乳腺白血病准则病人后卡培他中洲维持节拍复发的III期试制（SYSUCC-001）。

大舞台：乳腺白血病—全局/地区/借助于病人

所写：中所山大学防治一个中所心称王树森讲师等

简短号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

为了让前列腺癌脑的变异基本特征来分析十二指肠中所反应器DNA检测的概率: 取而代之基本功能结盟老获胜

大舞台：取而代之基本功能解决老关键问题

所写：李美芹 李科克等

简短号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

塔纳非尼对比索拉非尼作为末期肝线粒体白血病的梯队病人：一项全站首页、随机、多一个中所心II/III期试制。

大舞台：肠胃白血病—胃腹腔、肝脏和肝胆

所写：南京大学索科利夫卡疗养院毕锋讲师、中所国国民解放军八一疗养院秦叔逵讲师等

简短号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中所国末期肝白血病病人阿帕替尼二线病人：一项随机、安慰剂依此、结果表明III期研究课题

大舞台：肠胃白血病—胃腹腔、肝脏和肝胆

所写：中所国国民解放军八一疗养院秦叔逵讲师、南京大学索科利夫卡疗养院李秋讲师等

简短号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

末期患上性卵巢白血病二次线粒体减灭术的一项随机III期试制：SOC1 / SGOG-OV2。

回顾：诊疗白血病症

所写：上海交通大学附属中所山疗养院臧荣余讲师等

简短：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈白血病根治性子宫切除术后借助于病人中所的序贯放复发对比实质上化疗或同步放复发（STARS研究课题）：一项随机、依此、全站首页的III期试制。

大亦会：诊疗白血病症

所写：中所山大学防治一个中所心芙蓉讲师、刘继红讲师等

简短号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：借助于吉非替尼对比复发可用可切除的EGFR甲基化的N1-N2期NSCLC-随机III期诊疗试制的就此上都生存分析方法。

回顾：心脏病症—非小线粒体全局-地区/小线粒体/其他胸部

所写：广东省国民疗养院吴一龙讲师等

简短号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR甲基化寡转移非小线粒体心脏病症病人梯队酪氨酸趋化因子抗病毒合共同或不合共同积极前线全局化疗：III期全站首页诊疗随机试制（SINDAS）的中所期结果（NCT02893332）。

回顾：心脏病症-非小线粒体转移

所写：贵州省国民疗养院曾铭讲师等

简短：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性丧生-1（PD-1）的人源化IgG4单克隆抗体合共同阿昔替尼可用前列腺癌黏膜阿兹海默病人的Ib期研究课题的总生存期和生命体标志物分析方法。

回顾：阿兹海默/皮肤白血病

所写：北京大学疗养院郭军、盛锡楠讲师等

简短：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的相容性和结果：通用CAR-T线粒体首次药剂试制病人患上/难治性T线粒体急性淋巴线粒体白血病（r/r T-ALL）的相容性和。大亦会：开发计划中所的病人系统设计-免疫病人。所写：称陈刚欣等简短：3013宣传片：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在末期腹腔表皮线粒体白血病病人中所的运用：一项随机的全站首页II期试制（ORIENT-2）。大亦会：肠胃白血病-胃腹腔白血病、肝脏白血病和肝胆道白血病所写：徐建明讲师等简短：4511宣传片：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D免疫CAR-T线粒体对精母线粒体瘤的消弭性病人大亦会：中所枢神经系统所写：代红久、孙斌、杨东、徐晖、朱美美、魏佳、郑旭东简短：2522宣传片。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在末期错配修复缺陷病人中所的运用大亦会：开发计划中所的病人学-免疫病人所写：沈琳讲师等简短：3021宣传片。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 暂时性CD7-CART病人患上/难治性ACUTE淋巴线粒体白血病/淋巴瘤的首例药剂诊疗试制大亦会: 开发计划性病人学-免疫病人所写简介：张明志，杨林等简短：3026宣传片: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度酮（T）合共同应可用末期实体瘤病人的Ib期研究课题大亦会：发展性病人学----大分子凋亡药物和生命体学所写：龚继芳，沈琳讲师等简短：3523宣传片：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin合共同紫杉醇和nedaplatin病人患上性或前列腺癌腹腔表皮线粒体白血病（ESCC）病人的II期研究课题。大亦会：肠胃白血病-胃腹腔、肝脏和肝胆道白血病的研究课题所写：称王志弱，李玉红，称王德申，称王凤华，任超，谭琼 称王志弱、李玉红、称王德深、称王凤华、任超、谭琼简短：4522宣传片：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.大亦会：肠胃白血病-胃腹腔白血病、肝脏白血病和肝胆管白血病的二线病人所写：宋艳等简短：4524宣传片：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种粪便外体马蹄形RNA决策树可用初始活检时检测高等级白血病的粪便外体马蹄形RNA决策树：一项多一个中所心的回顾性研究课题大亦会：泌尿胎盘白血病症-----白血病、睾丸白血病和白血病所写简介：Liaoyuan Li等简短：5522宣传片。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 全局末期宫颈白血病并发复发后的借助于复发大亦会: 诊疗白血病症所写简介： 李珉珉等简短：6031宣传片：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼病人甲状腺精性白血病的相似性：基于ALTER01031试制的分析方法。亦会北京话：胸部所写：天津市疗养院高明讲师简短：6526宣传片。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、个数和年龄组对安洛替尼病人后病人结局的影响: ALTER01031的亚组分析方法大亦会：胸部所写：天津市疗养院高明讲师简短：6527宣传片。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析方法分析I-IIIA期非小线粒体心脏病症（NSCLC）病人术后患上: GASTO1035和GASTO1018的结果大亦会：心脏病症-非小线粒体全局-地区性/小线粒体/小线粒体/其他胸科白血病症所写：Si-Yu Wang等简短：9023宣传片：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小线粒体心脏病症（NSCLC）中所EGFR酪氨酸趋化因子抗病毒的取而代之型青霉素的系统大亦会:心脏病症-非小线粒体前列腺癌心脏病症所写简介：郑昕，金恰巧，满宇，欧秋香，才与，薛武，杨少，范敏 郑昕、金恰巧、满宇、欧秋香、才与、薛武、杨绍、范敏简短：9528宣传片：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试制中所末期阿兹海默总生存的替代绕道大亦会：阿兹海默/皮肤白血病所写：聂润聪，袁书弱，李元芳，陈英波，周志伟 聂润聪、袁书弱、李元芳、陈英波、周志伟简短：10030宣传片：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼病人患上或前列腺癌临床表现恶性颚骨病人的II期研究课题大亦会： 性疾病所写：唐丽娜，牛晓辉，称王稼祥，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、称王振、蔡启庆、涂崇奇、范正福、杨瑶简短：11525宣传片。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步赞扬安罗替尼在末期性疾病病人多线病人中所的相容性和。大亦会：性疾病所写：姚伟涛，来由弱，姚，称陈刚，杜取而代之辉，田志浩，牛晓颖 姚伟涛、来由弱、姚、称王鑫、杜鑫辉、田志超、牛晓英简短：11526宣传片：414